December 22, 2020—Polymed Biopharma recently submitted two patent applications for the discovery of novel PROTAC molecules for treatment of cancer and autoimmune diseases.  These molecules have demonstrated activities in the degradation of target proteins and proliferation inhibition of disease model cell line.  Polymed plans to further study the safety and effectiveness of these molecules in related animal disease models.

About Polymed. Polymed is a Hangzhou, China and Boston, USA based biotech company focusing on novel therapies in the areas of oncology and auto-immune diseases. We aim at creating first-in-class and best-in-class medicines for treating patients using advanced technology platforms including artificial intelligence and structural biology. The approaches we use includes classic protein inhibition and modern protein degradation. The aim is to deliver drugs for “undruggable” targets.